GRI Bio to Present Insights on Immune Modulation and Phase 2a Development at IPF Summit
News related to:GRI Bio, Inc · 2 min read
LA JOLLA, CA, Sept. 28, 2026 /CourierPR/ -- GRI Bio, Inc., a clinical-stage biotechnology company focused on developing therapies for inflammatory, fibrotic, and autoimmune diseases, will present at the 10th IPF Summit, taking place September 29 through October 1, 2026, in Boston, Massachusetts. The summit will feature presentations by the company's Chief Executive Officer, Marc Hertz, and Chief Scientific Officer, Vipin Kumar.
Hertz and Kumar will explore the role of immune biology in idiopathic pulmonary fibrosis (IPF) and discuss strategies for building predictive preclinical and translational development programs. Their talks will also delve into insights from Phase 2a development of a novel immune-modulating therapy, reflecting GRI Bio’s focus on advancing GRI-0621, its oral retinoic acid receptor (RAR) β/γ-selective agonist for the treatment of IPF.
GRI Bio, Inc. has a library of over 500 proprietary compounds, which it uses to fuel its growing pipeline of innovative therapies. The company’s lead program, GRI-0621, is being developed for the treatment of IPF, a progressive and life-threatening fibrotic lung disease with significant unmet need. The presentations aim to share perspectives from the company’s development program and engage with leaders in the field to advance GRI-0621.
The presentations at the 10th IPF Summit will provide valuable insights into GRI Bio’s ongoing research and development efforts, highlighting the company’s commitment to advancing therapies for IPF and other fibrotic diseases. The discussions will address how molecular and clinical findings can inform the development of treatments targeting the underlying drivers of fibrosis, reflecting GRI Bio’s focus on advancing GRI-0621.
Forward-looking statements in the press release include the potential benefits and impact of the company’s clinical trials and product candidates, the timing of initiation or completion of clinical trials and availability of resulting data, and the potential regulatory approval pathways for its products. The company cautions that actual results may differ from these statements due to various risks and uncertainties, including the accuracy of the estimated size and growth potential of the markets for the company’s products and its ability to serve those markets.
The release also notes that GRI Bio, Inc. is developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
The presentations at the 10th IPF Summit will provide a platform for GRI Bio to share its latest findings and engage with the broader scientific community. The summit will be a key opportunity to discuss how advances in immune biology and translational research can help shape the next generation of therapies for IPF.
The company’s focus on GRI-0621 and its broader pipeline underscores its commitment to addressing the significant unmet needs in the treatment of fibrotic and inflammatory diseases. The presentations will be part of a broader effort to advance the development of novel therapies that can improve patient outcomes and quality of life.